Commitments and Contingencies - Additional Information (Detail) |
9 Months Ended | ||
|---|---|---|---|
Mar. 12, 2021 |
Jan. 15, 2021 |
Sep. 30, 2022 |
|
| Loss Contingencies [Line Items] | |||
| Loss Contingency, Lawsuit Filing Date | January 15, 2021 | ||
| Loss Contingency, Name of Plaintiff | Genfit S.A | ||
| Loss Contingency, Allegations | alleging misappropriation of trade secrets and related causes of action based on the Company’s receipt of a Genfit protocol synopsis for Genfit’s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis | ||
| Loss Contingency, Actions Taken by Defendant | The Company intends to defend itself vigorously. While the outcome of any litigation is inherently uncertain, based on currently available information, management does not currently believe a loss associated with this matter is probable, nor is any amount reasonably estimable | ||
| Loss Contingency, Actions Taken by Court, Arbitrator or Mediator | On March 12, 2021, the Court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting the Company from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto. | ||
| Pending Litigation [Member] | |||
| Loss Contingencies [Line Items] | |||
| Loss Contingency, Lawsuit Filing Date | April 16, 2021 |